ReviewDrug design, development and therapy2025
Targeting Esophageal Cancer: Promising Drugs for the Clinical Landscape and Key Knowledge Gaps.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Response-adapted perioperative therapy for resectable esophageal cancer in the immunotherapy era: a narrative review.Journal of thoracic disease · 2026Review
- Immune exhaustion in esophageal cancer: interferon pathway dysregulation and neoadjuvant therapy response.Frontiers in cell and developmental biology · 2026Review
- Mechanism and therapeutic prospects of ferroptosis regulation through m6A in cancer.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Esophageal cancer remains a major global health burden, ranking seventh in cancer-related mortality. The prognosis is poor with five-year survival rates below 5% for metastatic disease. Tumor heterogeneity and the development of treatment resistance have limited durable responses to conventional chemotherapy. The emergence of biomarker-driven therapies has begun to transform management and enable more personalized treatment approaches. This narrative review summarizes current clinical strategies for esophageal cancer, emphasizing clinically validated biomarkers -HER2, PD-L1, CLDN18.2, and MMR/MSI status-that inform therapeutic selection for advanced metastatic disease. Both esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) are addressed; however, this review centers on biomarker-directed therapies for EAC, reflecting its predominance in Western populations and recent therapeutic progress. We highlight pivotal phase II and III clinical trials that have established the current landscape of esophageal cancer treatment. In addition, we review key early phase clinical data for promising new modalities such as antibody-drug conjugates, novel monoclonal antibodies, and cellular therapies-highlighting their biomarker associations and mechanisms of action. Finally, we discuss the ongoing challenges-including elucidating tumor heterogeneity, improving biomarkers, targeting novel tumor intrinsic vulnerabilities, overcoming treatment resistance, and preventing esophageal cancer development-and identify key research directions that present unique opportunities for the development of new biomarker-driven treatments for esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.